A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
Diabetic Gastroparesis
We are seeking Type 1 (T1DM) and Type 2 (T2DM) Diabetic men and women 18 to 75 years old, with at least a 3-month history of ongoing symptoms suggestive gastroparesis. who also have:
HgA1c <11.0% and treated for at least 3 months with oral and/or parenteral medications
Have had upper GI obstruction ruled out
At least two vomiting episodes 2 weeks prior to screening
Willing to comply with study procedures